CompletedPhase 2NCT01514526

Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma

Studying Adrenocortical carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Spanish Oncology Genito-Urinary Group
Principal Investigator
Jesús García-Donás Jiménez, MD, M.D., Ph.D
Spanish Oncology Genito-Urinary Group
Intervention
Dovitinib(drug)
Enrollment
17 enrolled
Eligibility
18 years · All sexes
Timeline
20122016

Study locations (7)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01514526 on ClinicalTrials.gov

Other trials for Adrenocortical carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Adrenocortical carcinoma

← Back to all trials